Sangui Biotech Financials
| SGBI Stock | USD 0 0.00 0.00% |
Sangui |
Understanding current and past Sangui Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Sangui Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Sangui Biotech's assets may result in an increase in income on the income statement.
The data published in Sangui Biotech's official financial statements usually reflect Sangui Biotech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Sangui Biotech Inter. For example, before you start analyzing numbers published by Sangui accountants, it's critical to develop an understanding of what Sangui Biotech's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Sangui Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sangui Biotech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Sangui Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sangui Biotech International. Please utilize our Beneish M Score to check the likelihood of Sangui Biotech's management manipulating its earnings.
Sangui Biotech Stock Summary
Sangui Biotech competes with Assertio Therapeutics, Amneal Pharmaceuticals, and Lifecore Biomedical. Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US80105B1017 |
| Business Address | BleichenbrUecke 9, Hamburg, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | NYSE Composite |
| Website | www.sanguibiotech.com |
| Phone | 49 40 609 3120 |
| Currency | USD - US Dollar |
You should never invest in Sangui Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Sangui Pink Sheet, because this is throwing your money away. Analyzing the key information contained in Sangui Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Sangui Biotech Key Financial Ratios
Generally speaking, Sangui Biotech's financial ratios allow both analysts and investors to convert raw data from Sangui Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Sangui Biotech over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Sangui Biotech Inter reports annually and quarterly.| Return On Asset | -0.64 | |||
| Beta | 0.22 |
Sangui Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sangui Biotech's current stock value. Our valuation model uses many indicators to compare Sangui Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sangui Biotech competition to find correlations between indicators driving Sangui Biotech's intrinsic value. More Info.Sangui Biotech International is currently regarded as top stock in return on asset category among related companies. It is currently regarded as top stock in profit margin category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sangui Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sangui Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sangui Biotech's earnings, one of the primary drivers of an investment's value.Sangui Biotech Inter Systematic Risk
Sangui Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sangui Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Sangui Biotech Inter correlated with the market. If Beta is less than 0 Sangui Biotech generally moves in the opposite direction as compared to the market. If Sangui Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sangui Biotech Inter is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sangui Biotech is generally in the same direction as the market. If Beta > 1 Sangui Biotech moves generally in the same direction as, but more than the movement of the benchmark.
About Sangui Biotech Financials
What exactly are Sangui Biotech Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Sangui Biotech's income statement, its balance sheet, and the statement of cash flows. Potential Sangui Biotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Sangui Biotech investors may use each financial statement separately, they are all related. The changes in Sangui Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sangui Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Sangui Biotech Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Sangui Biotech is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Sangui has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Sangui Biotech's financials are consistent with your investment objective using the following steps:- Review Sangui Biotech's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Sangui Biotech's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Sangui Biotech's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Sangui Biotech's stock is overvalued or undervalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangui Biotech International. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Sangui Biotech Inter information on this page should be used as a complementary analysis to other Sangui Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Sangui Pink Sheet analysis
When running Sangui Biotech's price analysis, check to measure Sangui Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangui Biotech is operating at the current time. Most of Sangui Biotech's value examination focuses on studying past and present price action to predict the probability of Sangui Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangui Biotech's price. Additionally, you may evaluate how the addition of Sangui Biotech to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |